Incretin and Glucagon Receptor Research: An Overview
A neutral introduction to GLP-1, GIP and glucagon receptor research and where multi-receptor agonists such as retatrutide fit in the scientific literature.
The receptors
Glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon act through related class B G-protein-coupled receptors. Each receptor has been studied extensively for its role in metabolic signalling.
From single to multi-receptor agonists
Research has moved from single-receptor agonists to molecules designed to act on two or three of these receptors. Retatrutide (LY3437943) is described in the literature as an agonist at GIP, GLP-1 and glucagon receptors and has been investigated in clinical research programmes by its developer.
Clinical investigation of a molecule does not make a research-grade material a medicine. Research peptides sold by Pepteria are for laboratory research only.
Finding primary sources
For current and accurate information, consult primary sources: peer-reviewed publications indexed in PubMed and trial registrations on ClinicalTrials.gov. Summaries — including this one — are no substitute for the original data.
Educational content for laboratory researchers. Products are for research use only and are not for human or veterinary use.